Selective Estrogen Receptor Modulators
DOI: 10.1007/3-540-34742-9_4
|View full text |Cite
|
Sign up to set email alerts
|

Cellular and Molecular Basis for Acute Nongenomically Mediated Actions of SERMs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 89 publications
0
2
0
Order By: Relevance
“…One example is the selective estrogen receptor modulators (SERMs). In addition to their estrogen receptor mediated anticancer genomic effects, SERMs share with antipsychotic drugs amphiphilic structure,65 calmodulin antagonist actions,65 and strongly upregulate expression of a similar set of cholesterol homeostasis genes to antipsychotic drugs,42 yet SERMs do not cause extrapyramidal or metabolic side effects 66. Hence, the findings of our study provide a rationale for future research investigating the effectiveness of combining statins with a broader range of amphiphilic compoundsas codrugs to augment standard anticancer chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…One example is the selective estrogen receptor modulators (SERMs). In addition to their estrogen receptor mediated anticancer genomic effects, SERMs share with antipsychotic drugs amphiphilic structure,65 calmodulin antagonist actions,65 and strongly upregulate expression of a similar set of cholesterol homeostasis genes to antipsychotic drugs,42 yet SERMs do not cause extrapyramidal or metabolic side effects 66. Hence, the findings of our study provide a rationale for future research investigating the effectiveness of combining statins with a broader range of amphiphilic compoundsas codrugs to augment standard anticancer chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…TX is a triphenylethylene molecule that competes the binding of 17β-estradiol to estrogen receptors (ER) and prevents the transcriptional activation of estrogen-dependent genes, which control the proliferation of mammary gland cells. However, tamoxifen is known to significantly enhance the risk of developing endometrial lesions, including hyperplasia, polyps, carcinomas, sarcoma, as well as womb cancer and thromboembolism [5][6][7][8][9][10]. Notably, tamoxifen-associated endometrial cancer often has a poor clinical outcome, and serious concerns exist on its use for cancer prevention or long-term palliative treatment [9,11].…”
Section: Introductionmentioning
confidence: 99%